Breast Cancer Briefing

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

BySara Nunnery, MD, MSCI,Sarah Sunshine, MD

August 4th 2026

Drs Nunnery and Sunshine discuss how breast cancer therapies affect the eye, beginning with a primer on ocular anatomy.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology in Nashville; Maelee Yang, MD, plastic surgeon, The Surgical Clinic; Odette Abou Ghanem, MD, assistant professor, plastic and reconstructive surgery, plastic and reconstructive surgeon, Vanderbilt University Medical Center

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

BySara Nunnery, MD, MSCI,Maelee Yang, MD ,Odette Abou Ghanem, MD

July 21st 2026

Drs Nunnery, Yang, and Abou Ghanem discuss available breast reconstruction options following breast cancer surgery.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; MinhTri Nguyen, MD, breast medical oncologist, assistant professor, lead faculty for Health Equity, Rush MD Anderson Cancer Center

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

BySara Nunnery, MD, MSCI,MinhTri Nguyen, MD

July 7th 2026

Drs Nunnery and Nguyen discuss the emergence of the oral SERD giredestrant in hormone receptor–positive, HER2-negative breast cancer management.

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

BySara Nunnery, MD, MSCI,Megan Kruse, MD

June 30th 2026

Drs Nunnery and Kruse discuss the controversy surrounding a biomarker-driven switch strategy in hormone receptor–positive, HER2-negative breast cancer.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; Vandana G. Abramson, MD, professor, medicine, co-leader, Breast Cancer Research Program, Breast Cancer Disease Team leader, Vanderbilt Health and the Vanderbilt-Ingram Cancer Center

Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

BySara Nunnery, MD, MSCI,Vandana G. Abramson, MD

June 16th 2026

Nunnery and Abramson discussed the transformative effects of next-generation oral SERDs in hormone receptor–positive breast cancer management.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; Annie Bond, breast cancer survivor, patient advocate

Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond

BySara Nunnery, MD, MSCI,Annie Bond

May 12th 2026

Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.

Sara Nunnery, MD, MSCI, Tennessee Oncology; Irene Morae Kang, MD, City of Hope Orange County

ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD

BySara Nunnery, MD, MSCI,Irene Morae Kang, MD

April 30th 2026

Drs Nunnery and Kang discuss the rapidly evolving treatment paradigm for first-line metastatic TNBC, including the emergence of novel ADCs.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology in Nashville; Neil M. Iyengar, MD, associate professor, co-director, Breast Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, director, Survivorship Services, Winship Cancer Institute of Emory University

Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

BySara Nunnery, MD, MSCI,Neil Iyengar, MD

April 16th 2026

Drs Nunnery and Iyengar highlight the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

BySara Nunnery, MD, MSCI,Neil Iyengar, MD

April 2nd 2026

Drs Nunnery and Iyengar discuss lifestyle and medical interventions pertinent to breast cancer survivorship.

Kelly E. McCann, MD, PhD, breast medical oncologist, University of California system; Sara Nunnery, MD, MSCI, breast medical oncologist, Tennessee Oncology

T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD

BySara Nunnery, MD, MSCI,Kelly E. McCann, MD, PhD

March 26th 2026

Drs Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm.

Breast Cancer Briefing

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond

ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD

Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD

Trending on OncLive

Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL

FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma

Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC

Dr Van Gorp on PFS Data With TUB-040 in Platinum-Resistant Ovarian Cancer

Neoadjuvant Ivonescimab Plus Chemotherapy Yields pCRs in Resectable HNSCC